Avantor (AVTR)
(Delayed Data from NYSE)
$24.08 USD
+0.48 (2.03%)
Updated May 31, 2024 04:00 PM ET
After-Market: $24.09 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Brokerage Reports
Avantor, Inc. [AVTR]
Reports for Purchase
Showing records 61 - 80 ( 132 total )
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
2022 Life Sciences and MedTech Conference: Day 1 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
COVID-19 Diagnostics: NT & LT Estimates Appear Conservative
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Preannouncement Dud, but Lonza Day Suggests Dandy Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
''Thermoesque'' Business Model Driving Multiple Expansion; Raise PT to $51
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
The "New" Avantor Beginning to Shine - Raising PT to $45
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Life Science Tools - Vaccine, Bioproduction, mRNA, Cell & Gene Therapy and M&A: 2H21 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Post 1Q Beat & Raise and Likely to Exceed Estimates in FY21
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department